board performance report performance report · page 1 of 32 board performance report performance...

of 32

Board Performance Report Performance Report

For the period ended 30 th April 2017

S

tatu

s

T

rend

Comments

Blood Components

Red cell issues in April were 11.4% lower than last year (although 2% on a true like for like basis) and 4.1% lower than plan. As a result stocks rose to around 38k with all groups above alert level and O neg stocks above 5 days. Platelet issues in April were 2.6% lower than last year (in line with plan).

DTS

A positive income trend in TAS, RCI and SCDT continues but income in TES was behind plan. There were 7 cord blood unit issues versus 5 planned. Cornea stock was at 297 end April.

ODT

There were 113 deceased donors in April (versus plan of 127). The number of transplants was also below plan (275 vs 343). Living Donors (reported one month in arrears) were 17.5% lower than plan for the full year 2016/17.

Corporate

Sickness absence reduced further to 3.2% an ongoing positive trend in H&S.

Finance

A deficit of £0.6m was reported in April, £1.2m better than plan.

Change Programme

The overall transformation programme is reporting at Amber status. The only red project is the Desktop project where technical issues have been encountered that will require external resource to resolve. The Core Systems Modernisation and ODT Hub projects are both reporting at Amber status.

Contents Pages 1. Performance Summary 1 2. Blood Components - Summary 2-12 3. DTS – Summary 13-19 4. ODT – Summary 20-26 5. Group Level Trends 27-29 6. Risk Management 30-31 7. Financial Report 32

of 32

DIVISION PILLAR BLODD 2020 – STRATEGIC TARGETS YTD RAG

RAG CHANGE

PERFORMANCE

72% of blood donors scoring =/> 9/10 for satisfaction. G - Ahead of plan in April (78.5% vs 75%) - Chart 15.

No. of complaints per million donation G - Better than plan at 0.34% (vs 0.44%) - Chart 16

Number of Donors Donating over the last 12 months (000’s) G - Below plan in April (848k vs 855) - Chart 23.

Frequency of Donation (overall) G - Lower than plan in April – 1.867 vs 1.880 (Chart 23).

Number of O- neg Donors donating last 12 months (000’s) G - Worse than plan in April (104.8k vs 105.9k) - Chart 24.

Frequency of Donation (O neg donors) G - 1.965 in April (vs 1.975 planned) - Chart 24.

Recruitment of new black donors - 13k (new metric) R April below target – 285 versus 749 target.

% of whole blood donations in donor centres G - April 17 18.99% - equal with plan

% of 9 bed sessions G - Better than plan in April 17 at 69.2% (vs 65%)

Blood Donation and the Donor Experience

Blood Donation Productivity: units/FTE/year G - April 17 at 1,340 vs plan of 1,348 – charts 27/28

Red Cell Blood Stocks – Alert Levels G - Above3 day alert for all groups - (chart 13).

Platelet Demand vs. Stock levels A - Below target on one occasion: - chart 14.

Number of ‘critical’ and “major” regulatory non-compliances G - None reported in April (reported in month).

96.5% of Products Issued on Time G - Better than plan in April (97% vs 96.5%) - chart 29.

Manufacturing Productivity (units/FTE/year) G - April 1lower than plan (9.6k vs 9.7k) - Chart 25

BLOOD

Supply-Chain Operations

Testing Productivity (units/FTE/year) G - April 2017 reporting 27.2k vs plan of 27.0k) - Chart 26.

of 32

Red Cell Usage (units per thousand of population – target 28 - New measure to be reported quarterly – first report:

June 2017. Customer Service and the Hospital Interface

70 % hospitals scoring =/> 9/10 for satisfaction (chart 30). - - March at 76% (better than target). Next survey June 2017.

• Red cell issues in April were 11.4% lower than last year. However, this was impacted by the transfer to the Welsh Blood Service during 2016/17 and the frequency of Bank Holidays such that the underlying like for like decline was more like 2%. This was 4.1% lower than plan and, with collections 0.9% higher than plan, stocks consequently rose to around 38k for much of the month. Within this all blood groups remained > 3 day alert level and O neg stocks were above 5 days.

• The demand forecast for red cells in 2017/18 has increased to 1.464m issues (versus 1.461m agreed with the NCG). The trend in average week day issues is

indicating that the underlying demand position may be starting to flatten.

• Pressure on O neg supply remains. The proportion of O neg issue to the total rose to 13.4% in April (versus 13.1% for full year 2016/17). Demand continues to fall, however, and hence the pressure continues to reflect the substitution of Ro units with O neg units (as noted in the OTIF comment below).

• Platelet issues in April were in line with plan and 2.6% lower than last year. The forecast for 2017/18 is 250.7k, lower than agreed with the NCG (256k).

• The CD share of issued platelets was higher in April at 57.8% (March at 55.3%), although lower than the previous year (59.4%). • AB platelet stocks were below alert level for two days on one occasion. Stocks of Group A- platelets were above the 1 day stock alert level on 17/18 working

days during the month. • OTIF in April continued to be strong, and in line with last month, at 97.0% (vs target of 96.5%). Meeting demand for Ro units continues to be the primary issue

with an OTIF of 52% for these units in April. Performance was impacted by both a small fall in the active Ro donor base and lower collections in the month (which were only 71% of plan). New targets and plans are being developed for recruitment of the additional black donors that will be necessary to meet the demand for Ro units with £1m set aside in transformation funds to pay for this new activity. Recruitment of new black donors was behind plan in April.

• The red cell loss rate was sharply higher in April at 4.50% (and above plan of 3.60%). The level of underweight collections continues to be an issue but it was

also impacted by an incorrect delivery of red cells to Newcastle rather than Manchester over the Bank Holiday. The underweight issue may have been impacted by recent guidance on needle insertion and restriction on the number of adjustments that can be made. The red cell expiry rate was also sharply higher in April at 1.44% (and above target of 1.25%) primarily reflecting over collection of certain blood groups versus demand.

• Platelets issued / produced was higher in April at 90.36%, although again behind plan. Platelet expiries were also higher in April at 7.14% and well above

target of 6.17%.

• The number of faints in the month was higher at 160 but in line with target. The number of rebleeds was better than plan at 26 (vs target of 30).

of 32

• Donor satisfaction was higher this month at 78.5%. This is better than target of 75% and is the second highest return ever reported. Donor complaints (excluding those complaints related to consolidation / team closures and also those related to cancellation of sessions) were lower this month at 3.4k - better than plan of 4.4k.

• Sickness absence improved with blood donation at 4.45% and logistics at 5.5% (versus target of 5%).

• There were no major non-compliances reported during April. In early May, however, one major has been recorded following the MHRA inspection at Manchester.

This was made up of around 7 items related to investigations of incidents, root cause analysis and corrective and preventive action records. Most were not significant in themselves, but collectively the inspector drew a conclusion that it ranked as a major overall.

• There were 5 SABRE incidents in the month with 2 relating to the supply of non-irradiated units when radiated units had been ordered. The units were not

transfused but root cause investigations are underway. Blood Supply – Status of Strategic Projects per TPB reporting:

Project title Status This RAG

Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)

F/cast Benefit (£m’s)

Planned to

complete

F/Cast to

complete Planning and Control System Delivery G A 1.0 0.9 0.1 (i) Jul 15 Jun 17 Supply Chain Modernisation (National Operations) Delivery G G 6.5 6.5 1.3 Oct 17 Oct 17

Core Systems Modernisation Define A A 11.4 (ii) (1.6) 7.6 1.5 Jan 20 Dec 19

Euro Blood Pack 2 Delivery G G 0.4 0.3 1.9 Aug 18 Jun 18 Leicester Donor Centre Initiation G G 0.9 (iii) 0.9 0.1 May 18 Aug 18 Session of the Future Start-Up G A 0.2 0.2 N/A May 19 May 19 Bradford Donor Centre Delivery G G 0.8 0.8 0.1 Sep 17 Sep 17 HEV Universal Screening Delivery G G 0 (iv) N/A N/A Jun 17 Jun 17 Platelet Supply Phase 2 Delivery G G 1.0 0.9 0.8 Nov 17 Nov 17

Note:

i) Updated figure to be provided next month; ii) This is the non recurring figure for 2017/18; recurrent figure is shown in brackets; iii) New budget agreed at OBC by TPB in February 2017, with detailed costs to be submitted in the DBC (expected August 2017); iv) No project budget stated, as contract related costs do not form part of project budget.

1. On-Session Adverse Events - Faints & Rebleeds per 10,000 Donors Bled 2. Major QIs raised per month - Blood Supply Directorate

3. SABRE Events Reported per Month 4. % of Patients Receiving Grade A or B1 HLA Matched Platelets H&I # 5

Annual

Target

YTD

TargetYTD Actual RAG

YTD RAG

Trend

75.0% 75.0% 72.6% A -

YTD Performance

% of patients receiving A or B1 platelets

Monthly Performance Report - As at the end of April 2017

Blood Components - Safety and Compliance

0

20

40

60

80

100

120

140

160

180

200

Ma

y-1

6

Jun-1

6

Ju

l-1

6

Aug-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Fe

b-1

7

Ma

r-1

7

Apr-

17

Faints Actual Rebleeds Actual Faints Plan Rebleeds Plan

0

1

2

3

4

5

6

Ma

y-1

6

Jun-1

6

Jul-1

6

Au

g-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Ja

n-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

SABRE Actual Target

0

5

10

15

20

25

30

35

40

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

Blood Donation Manufacturing & Logistics

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

70.0%

80.0%

90.0%

Ma

y-1

6

Jun-1

6

Ju

l-1

6

Au

g-1

6

Sep-1

6

Oct-

16

Nov-1

6

De

c-1

6

Ja

n-1

7

Feb-1

7

Ma

r-1

7

Apr-

17

Grade A Grade B1 Target

Monthly Performance Report: As at the end of April 2017 of 32

5. Average Weekday Red Cell Issues By Month ->April 2015 6. MAT Red Cells and O Neg Issues (Adult Equivalant Units) - 000's

7. Red Cell Supply - Year to Date by Blood Group 8. Red Cell - Blood Stocks (Units)

A Neg

A Pos

AB Neg

AB Pos

B Neg

B Pos

O Neg

O Pos

Total 113,915 128,635 -11.4%

15,263 16,568 -7.9%

40,777 45,582 -10.5%

2,713 3,310 -18.1%

8,743 10,269 -14.9%

939 961 -2.3%

2,576 2,652 -2.9%

9,203 10,595 -13.1%

33,702 38,699 -12.9%

Blood Components - Red Cell Issues / Stocks

Blood Group2017/18 - YTD

April 2017

2016/17 - YTD

April 2016Change

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

1,400

1,450

1,500

1,550

1,600

1,650

1,700

1,750

1,800

1,850

1,900

1,950

2,000

2,050

2,100

2,150

2,200

Apr-

05

Oct-

05

Apr-

06

Oct-

06

Apr-

07

Oct-

07

Apr-

08

Oct-

08

Apr-

09

Oct-

09

Apr-

10

Oct-

10

Apr-

11

Oct-

11

Apr-

12

Oct-

12

Apr-

13

Oct-

13

Apr-

14

Oct-

14

Apr-

15

Oct-

15

Apr-

16

Oct-

16

Apr-

17

O N

eg

Is

su

es

Re

d C

ell

Is

su

es

(in

cl.

O n

eg

)

Red Cell Issues (all groups) MAT Red Cell Issues (O Neg) MAT

000's000's

4,500

4,700

4,900

5,100

5,300

5,500

5,700

5,900

6,100

6,300

Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar

Ave

rag

e W

ee

kd

ay I

ss

ue

s

2015/16 2016/17 Plan 1,461k 2017/18

Latest data point is part month

20,000

25,000

30,000

35,000

40,000

45,000

50,000

55,000

Ma

y

Jun

Jul

Aug

Sep

Oct

No

v

De

c

Jan

Feb

Ma

r

Apr

Yr to 13 May 2016 Yr to 12 May 2017


9. Average Weekday Platelet Issues By Month ->April 2014 10. MAT Platelet and A Neg Issues (Adult Therepeutic Doses) - 000's

11. MAT UK (Non MB) FFP and UK (Non MB) Cryo Pools - 000's 12. MAT Meth Blue FFP and Meth Blue Cryo Pools

Blood Components - Platelet Issues

Blood Components - Blood Collection: Frozen Component Issues

0

500

1,000

1,500

2,000

2,500

3,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

10,000

Ma

r-10

Ju

n-1

0

Se

p-1

0

De

c-1

0

Ma

r-11

Ju

n-1

1

Se

p-1

1

De

c-1

1

Ma

r-12

Ju

n-1

2

Se

p-1

2

De

c-1

2

Ma

r-13

Ju

n-1

3

Se

p-1

3

De

c-1

3

Ma

r-14

Ju

n-1

4

Se

p-1

4

De

c-1

4

Ma

r-15

Ju

n-1

5

Se

p-1

5

De

c-1

5

Mar-

16

Jun

-16

Se

p-1

6

Dec-1

6

Mar-

17

Me

th B

lue

FF

P

MAT : MB FFP MAT : MB Cryo Pools

18

20

22

24

26

28

30

32

34

36

150

160

170

180

190

200

210

220

230

240

250

260

270

Mar-

10

Jun

-10

Se

p-1

0

Dec-1

0

Mar-

11

Jun

-11

Se

p-1

1

Dec-1

1

Mar-

12

Jun

-12

Se

p-1

2

Dec-1

2

Mar-

13

Jun

-13

Se

p-1

3

Dec-1

3

Mar-

14

Jun

-14

Se

p-1

4

Dec-1

4

Mar-

15

Jun

-15

Se

p-1

5

Dec-1

5

Mar-

16

Jun

-16

Se

p-1

6

Dec-1

6

Mar-

17

UK

Cry

o P

oo

ls (

000s)

UK

FF

P (

000

s)

MAT : UK FFP (000s) MAT : UK Cryo Pools (000s)

26

30

34

38

42

200

220

240

260

280

300

320

Apr-

12

Ju

l-1

2

Oct-

12

Jan-1

3

Apr-

13

Ju

l-1

3

Oct-

13

Jan-1

4

Apr-

14

Ju

l-1

4

Oct-

14

Jan-1

5

Apr-

15

Ju

l-1

5

Oct-

15

Jan-1

6

Apr-

16

Ju

l-1

6

Oct-

16

Jan-1

7

Apr-

17

A n

eg

Issu

es

AT

D P

late

let

Iss

ue

s (

inc

l. A

ne

g)

Platelet Issues (all groups) MAT Platelet Issues (A Neg) MAT

000's 000's

750

770

790

810

830

850

870

890

910


Ave

rag

e W

ee

kd

ay I

ss

ue

s

2015/16 2016/17 Plan 251k 2017/18

Latest data point is part month


13. Red Cell - O neg : weekday stock levels BC # 3 14. Total Platelet / A neg stock levels BC # 4

YTD Performance Annual TargetYTD

TargetYTD Actual

YTD

RAG

YTD RAG

TrendYTD Performance

Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

Number of occasions where red cell stocks (for

any blood group) are below the three day alert

level for three or more consecutive days

0 0 0 G -

Number of occasions where opening stock of

platelets (for any blood group) is below average

daily demand for two or more consecutive days

0 0 1 A -

15. Donor Satisfaction BC # 5 16. Donor Complaints BC # 10

YTD Performance Annual TargetYTD

TargetYTD Actual

YTD

RAG

YTD RAG


Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

% of donors scoring >= 9/10 for satisfaction 75.0% 75.0% 78.5% G - Number of complaints per million donations 4,400 4,400 3,400 G -

Blood Components - Vulnerable Stocks

Blood Components - Blood Donor Base

1.50

2.50

3.50

4.50

5.50

6.50

7.50

16

-Ma

y-1

6

30

-Ma

y-1

6

13

-Ju

n-1

6

27

-Ju

n-1

6

11

-Ju

l-1

6

25

-Ju

l-1

6

08

-Au

g-1

6

22

-Au

g-1

6

05

-Se

p-1

6

19

-Se

p-1

6

03

-Oct-

16

17

-Oct-

16

31

-Oct-

16

14

-No

v-1

6

28

-No

v-1

6

12

-De

c-1

6

26

-De

c-1

6

09

-Ja

n-1

7

23

-Ja

n-1

7

06

-Fe

b-1

7

20

-Fe

b-1

7

06

-Ma

r-1

7

20

-Ma

r-1

7

03

-Ap

r-1

7

17

-Ap

r-1

7

01

-Ma

y-1

7

O- Alert Linear (O-)Days stock

0.00

0.75

1.50

2.25

3.00

3.75

01-D

ec-1

6

08-D

ec-1

6

15-D

ec-1

6

22-D

ec-1

6

29-D

ec-1

6

05-J

an-1

7

12-J

an-1

7

19-J

an-1

7

26-J

an-1

7

02-F

eb-1

7

09-F

eb-1

7

16-F

eb-1

7

23-F

eb-1

7

02-M

ar-

17

09-M

ar-

17

16-M

ar-

17

23-M

ar-

17

30-M

ar-

17

06-A

pr-

17

13-A

pr-

17

20-A

pr-

17

27-A

pr-

17

04-M

ay-1

7

11-M

ay-1

7

Total Platelet Stocks Alert Level A-

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

20

10

/11

FY

20

11

/12

FY

20

12

/13

FY

20

13

/14

FY

20

14

/15

FY

20

15

/16

FY

20

16

/17

FY

Ap

r-1

7

Ma

y-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Ma

r-1

8

Donor Satisfaction - Actual Donor Satisfaction - Plan

0

200

400

600

800

1,000

1,200

Apr-

15

Jun-1

5

Aug-1

5

Oct-

15

Dec-1

5

Feb-1

6

Apr-

16

Jun-1

6

Aug-1

6

Oct-

16

Dec-1

6

Feb-1

7

Apr-

17

To

tal n

um

be

rs -

fo

r C

om

pla

ina

nts

wit

h D

on

ati

on

s f

ac

tore

d b

y 1

/25

0 t

o

fit

ch

art

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

Ra

tio

/ m

illio

n

Collections/250 Complainants Complainants/million donations


17. O neg RC Demand and Issues 18. A neg Platelet Demand and Issues

19. Percentage of Donations NOT Converted to Validated Red Cells and Expiries 20. Percentage of Platelets Produced NOT Issued

Blood Components - Red Cell Demand/Issues (O Neg) and Platelet Demand/Issues (A Neg)

Blood Components - Wastage

12000

13000

14000

15000

16000

17000

18000

19000

41730 41821 41913 42005 42095 42186 42278 42370 42461 42552 42644

O- Demand O- Issues

12,000

13,000

14,000

15,000

16,000

17,000

18,000

19,000A

pr-

14

Jun

-14

Aug

-14

Oct-

14

Dec-1

4

Feb

-15

Apr-

15

Jun

-15

Aug

-15

Oct-

15

Dec-1

5

Feb

-16

Apr-

16

Ju

n-1

6

Aug

-16

Oct-

16

Dec-1

6

Feb

-17

Apr-

17

O- Demand O- Issues

2,000

2,200

2,400

2,600

2,800

3,000

3,200

3,400

3,600

3,800

4,000

4,200

Apr-

14

Ju

n-1

4

Au

g-1

4

Oct-

14

Dec-1

4

Feb

-15

Apr-

15

Ju

n-1

5

Au

g-1

5

Oct-

15

Dec-1

5

Fe

b-1

6

Apr-

16

Ju

n-1

6

Aug-1

6

Oct-

16

Dec-1

6

Fe

b-1

7

Apr-

17

A- Demand

A- Issues

0.00%

0.50%

1.00%

1.50%

2.00%

2.50%

3.00%

3.50%

4.00%

4.50%

5.00%

20

10

/11 F

Y

20

11

/12 F

Y

20

12

/13 F

Y

20

13

/14 F

Y

20

14

/15 F

Y

20

15

/16 F

Y

20

16

/17 F

Y

Ap

r-17

May-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

Actual Process Losses Plan Process Losses Actual Expiries Plan Expiries

0.00%

2.50%

5.00%

7.50%

10.00%

12.50%

15.00%

17.50%

20.00%

22.50%

20

10

/11 F

Y

20

11

/12 F

Y

20

12

/13 F

Y

20

13

/14 F

Y

20

14

/15 F

Y

20

15

/16 F

Y

20

16

/17 F

Y

Ap

r-17

May-1

7

Ju

n-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

Pooled CD Period Total YTD Total Plan YTD


21. Donor Recruitment (Whole Blood) 22. Donor Retention Rate (Whole Blood)

23.Donor Base and Frequency of Donation BC # 6 BC # 7 24. O Neg: Donorbase and Frequency of Donation BC # 8 BC # 9

YTD PerformanceAnnual

TargetYTD Target YTD Actual

YTD

RAG

YTD RAG


Annual

TargetYTD Target YTD Actual

YTD

RAG

YTD RAG

Trend

Number of donors donating in the last 12

months838,342 855,478 848,027 G -

Number of active O neg donors donating over

the last 12 months107,513 105,932 104,768 G -

Frequency of donation (overall) 1.880 1.880 1.867 G - Frequency of donation (O neg donors) 1.975 1.975 1.965 G -

Blood Components - Donor Recruitment and Retention

1.838

1.888

1.938

1.988

2.038

2.088

2.138

100,000

101,000

102,000

103,000

104,000

105,000

106,000

107,000

108,000

109,000

110,000

Ma

y-1

6

Jun-1

6

Ju

l-1

6

Aug-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

O-neg Donors Donating O-neg Frequency

78%

79%

80%

81%

82%

83%

84%

85%

86%

Donors returning to donate within 12 months

All Groups

O-negative

76.0%

78.0%

80.0%

82.0%

84.0%

86.0%

88.0%

May-1

6

Ju

n-1

6

Ju

l-1

6

Aug

-16

Se

p-1

6

Oct-

16

Nov-1

6

De

c-1

6

Ja

n-1

7

Feb-1

7

Ma

r-1

7

Ap

r-1

7

Donors returning to donate within 12 months

All Groups O Negative

1.750

1.800

1.850

1.900

1.950

2.000

2.050

2.100

750,000

770,000

790,000

810,000

830,000

850,000

870,000

890,000

Ma

y-1

6

Jun-1

6

Jul-

16

Aug-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Ja

n-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Donors Donating (All Groups) Average Frequency (All Groups)

0

2,000

4,000

6,000

8,000

10,000

12,000

14,000

16,000

18,000

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Ja

n-1

7

Fe

b-1

7

Ma

r-1

7

Ap

r-1

7

New Donors Donating - Vulnerable New Donors Donating - Other New Recruits Attending


25. Processing Productivity : YTD and Current Month BC # 17 26. Testing Productivity : YTD and Current Month BC # 18

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

10,300 9,660 9,625 G - 29,700 27,058 27,204 G -

27. Blood Donation Productivity : YTD and Current Month BC # 19 28. Blood Donation Productivity - Distribution Mobile Teams

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

1,411 1,348 1,340 G -

Blood Components - Productivity

YTD Performance

Testing productivity (units/FTE/year)

YTD Performance

Manufacturing productivity (units/FTE/year)

YTD Performance

Blood Donation Productivity (units/FTE/Year)1,3

40

1,3

40

900

1,000

1,100

1,200

1,300

1,400

1,500

1,600

1,700

1,800

1,900

200

8/0

9

200

9/1

0

201

0/1

1

201

1/1

2

201

2/1

3

201

3/1

4

201

4/1

5

201

5/1

6

201

6/1

7

201

7/1

8 Y

TD

201

7/1

8P

eri

od

EBA Top Quartile 1,752

9,6

25

9,6

25

4,000

5,000

6,000

7,000

8,000

9,000

10,000

11,000

200

8/0

9

200

9/1

0

201

0/1

1

201

1/1

2

2012/1

3

201

3/1

4

201

4/1

5

201

5/1

6

201

6/1

7

2017/1

8 Y

TD

2017/1

8P

eri

od

EBA Top Quartile 9,749

27,2

04

27,2

04

5,000

10,000

15,000

20,000

25,000

30,000

35,000

200

8/0

9

200

9/1

0

201

0/1

1

201

1/1

2

201

2/1

3

201

3/1

4

201

4/1

5

2015/1

6

201

6/1

7

201

7/1

8 Y

TD

201

7/1

8P

eri

od

EBA Top Quartile23,996

1,050

1,150

1,250

1,350

1,450

1,550

1,650

1,750

YTD Average includes static sites

27 above average

Reading (1,756)Slough (1,609)London Middlesex (1,575)Coventry (1,520)Northwich (1,505)

23 below averageSouth Anglia (1,142)Sheffield South (1,117)Portsmouth (1,034)City (1,034)Thetford (970)

Top 5

Bottom 5


29. Percentage of Products Issued OTIF BC # 1 30. Hospital Satisfaction - next survey results due in June 2017 BC # 2


Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG


Annual

Target

YTD

Target

YTD

Actual

YTD

RAG

YTD RAG

Trend

% On Time In Full delivery 96.50% 96.50% 96.99% G - Hospitals rating satisfaction at >/=9/10 70% 70% 76% G -

Blood Components - Customer Service

70% 70% 70% 70%

75%

67%

85%

76%

50%

54%

58%

62%

66%

70%

74%

78%

82%

86%

90%

Jun-1

6

Se

p-1

6

De

c-1

6

Ma

r-1

7

Plan Actual

90.0%

91.0%

92.0%

93.0%

94.0%

95.0%

96.0%

97.0%

98.0%

99.0%

100.0%

Ma

y-1

6

Jun-1

6

Ju

l-1

6

Au

g-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Ap

r-1

7

OTIF Actual OTIF Plan


of 32

DIVISION THEME STRATEGIC TARGET YTD RAG

RAG CHANGE PERFORMANCE

Sales Income (£69.3m) G - Ahead of plan in April (£5.8m vs £5.2m).

Number of Serious Incidents (SI’s) G - None reported this month

Zero ‘critical’ regulatory non-compliances G - None reported in April.

Group Targets

Number of ‘major’ regulatory non-compliances G - None reported in April

Sales income achieved - £13.6m (chart 31) R - Worse than plan (£0.9m vs plan of £1.1m).

80% percent of customers scoring =/> 9/10 for satisfaction with Tissues A - March 2017 (reported in April 2017) at 75%.

Tissue & Eye Services

98.0% of Product issued on time G - Better than plan (100% vs 98.0%).

Sales Income achieved - £13.9m (chart 32) G - Higher than plan this month (£1.1m vs £1.0m).

% of patients receiving A or B1 platelets A - Below plan in April (72.6% vs 75%) - Chart 4 -

Time to type DCD organ donors G - Reporting monthly in arrears - at 90% vs target of 80%.

H&I

Turnaround time vs SLA (chart 36) A - Behind plan in April (92.6% vs 95%).

£14.95m Sales income achieved (chart 32) G - Ahead of plan in April (£1.2m vs £1.1m)

DTS

RCI Sample turnaround time vs SLA (chart 35) G - April better than plan at 98.6% (vs plan of 95%)

of 32


RAG CHANGE PERFOMANCE

£11.2m sales income achieved (chart 33) G - Better than plan in April (£0.7m vs £0.6m). CMT

On time in full – target 100% G At target in April.

£9.8m sales income achieved (chart 33) G - Income above target (£1.1m vs £0.8m)

% Confirmatory typing within 14 days R - Lower than target in April (72% vs 80%)

2,300 increase to Banked Cords TNC > 140 R - Behind plan in April (171 vs 191)

40% BAME Cord Blood units add to the bank A - 38% in April (> 40).

Issue 53 Cord Blood units G - Better than plan with 7 units issued (vs 5).

Adult Donor Provisions R - Lower than plan his month (15 vs 16).

SCDT

Donors recruited to fit panel – 10k A - Worse than plan in April (796 vs 833)

£7.6m sales income achieved (chart 34) G - Better than plan in April (£0.6m vs £0.5m)

62% of hospitals scoring =/> 9/10 for satisfaction - - 70.5% vs 62% at February.2017.

DTS

Therapeutic Apheresis Services

95% of Patients rating patient experience =/>9/10 - - Latest survey, reported in December 2016 at 93% (vs 95%)

• An I&E surplus of £0.7m was recorded for DTS in April. There were a number of accounting treatment errors, however, with income overstated in H&I by £142k

and SCDT by £170k. The more accurate position is therefore a £0.4m favourable income variance (+12% versus last year). • Sickness absence in DTS was flat at 2.86% (versus target of 4%).

of 32

DTS Income by SBU – YTD April 2017

2017/18 Budget

2017/18 Income

2017/18 Variance

2016/17 Actual

Growth

Tissue & Eye Services 1.1 0.9 -0.2 1.0 -6% TAS 0.5 0.6 0.1 0.5 24% H&I 1.0 1.1 0.1 1.1 2% RCI 1.1 1.2 0.1 1.1 8% IBGRL & DD 0.1 0.1 0.0 0.1 55% CMT 0.7 0.7 0.1 0.7 7% SCDT 0.8 1.0 0.3 0.6 76% Customer Services 0.0 0.0 0.0 0.0 -8% Total (£m’s) 5.2 5.8 0.5

5.1 14% • Tissue and Eye Services - income in April was 14% behind plan and 6% behind last year. Strong sales were seen in DBM, ASE/AlloSE, tendons and dCELL

dermis, albeit that this was more than offset by the underperformance of corneas, skin, bone, CV and femoral heads. Eye bank stocks were at 297 end of April and close to the ideal range of 300-350.

• RCI income was 9.6% better than plan in April and 8.5% higher than last year. There was also a small favourable position on expenditure generating a small

surplus contribution of £0.1m. All labs performed well with critical sample turnaround at 100% and sample turnaround ahead of plan at 98.6%. • H&I reported income was better than plan but, taking account of a reporting error, the underlying position was marginally below plan. Activity in both solid organ

and stem cell investigations were lower than plan and continue the trend seen last year. Turnaround times have continued to run behind plan and were reporting at 93% in the month (vs 95% target). The provision of A and B1 matched platelets was 73%, worse than target (75%).

• Stem Cell Donation & Transplantation reported income was higher than plan, and when corrected for a reporting error remained, £0.1m favourable. There were 7 cord issues in the month (versus target of 5) with 3 in the UK and 4 international. 15 BBMR donors were provided (versus target of 16) with the UK 5 behind plan and international 4 ahead of plan. The IT connection with US registries is now in place and has resulted in increased activity. The number cord units banked continues to run behind plan (10% behind in the month). BAME cord donations banked were also behind target in the month (at 38% versus target of 40%). Cellular and Molecular Therapies - service income in April higher than plan (£0.7m vs £0.6m planned). Minimal income was received in April in respect of advanced cell therapies and CBC (and in line with phasing).

• Therapeutic Apheresis Services income in April 2017 was higher than plan and 24% ahead of 2016/17, primarily due to strong performance on Plasma

Exchange and ECP. The income surplus, when combined with a small expenditure under spend, is provided a favourable contribution surplus of c£0.2m.

• There were no critical/major non-compliances reported in April.

of 32

DTS – Status of Strategic Projects per TPB reportin g:

Project title Status This

RAG Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)


Planned to complete

F/Cast to complete

Stock Management Rollout Delivery A G 0.3 0.3 N/A Jul 17 Jul 17 TAS - Liverpool Start-Up G G TBC TBC TBC Feb 19 Mar 20 Filton Extension Start-Up G G 0.2 0.2 N/A Mar 19 Mar 19

31. Tissue and Eye Services Income (MAT) TS # 1 32. Diagnostic Service Income (MAT) H&I # 1 RCI # 1

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual

TargetYTD Target YTD Actual RAG

YTD RAG

Trend

14.884 1.113 1.220 G -

13.882 0.998 1.086 G -

33. Stem Cells - SCDT/CMT Income (MAT) CMT # 1 SCDT # 1 34. Therapeutic Apheresis Services Income (MAT) TAS # 1

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual


YTD RAG

Trend

11.212 0.669 0.736 G -

9.795 0.764 1.048 G -

Income (£m's) - H&IIncome (£m's) - TES 13.602 1.081 0.919

Income (£m's) - RCI

Diagnostic and Therapeutic Services - Income

YTD Performance YTD Performance

-

YTD Performance

Income (£m's) - CMT

Income (£m's) - SCDT7.581 0.526 0.638 G

YTD Performance

Income (£m's) - TAS

R -

7,000

8,000

9,000

10,000

11,000

12,000

13,000

14,000

15,000

Ap

r-14

Jun

-14

Au

g-1

4

Oct-

14

Dec-1

4

Feb-1

5

Ap

r-15

Jun

-15

Au

g-1

5

Oct-

15

Dec-1

5

Feb-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

De

c-1

6

Feb-1

7

Ap

r-17

Ju

n-1

7

Au

g-1

7

Oct-

17

De

c-1

7

Feb-1

8

£000s

TES Actual TES Budget

11,500

12,000

12,500

13,000

13,500

14,000

14,500

15,000

15,500

Ap

r-14

Jun

-14

Au

g-1

4

Oct-

14

Dec-1

4

Fe

b-1

5

Ap

r-15

Jun

-15

Au

g-1

5

Oct-

15

Dec-1

5

Fe

b-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

Dec-1

6

Feb-1

7

Ap

r-17

Jun

-17

Au

g-1

7

Oct-

17

Dec-1

7

Feb-1

8

£000s

H&I Actual RCI Actual H&I Budget RCI Budget

4,500

5,000

5,500

6,000

6,500

7,000

7,500

8,000

8,500

Ap

r-1

4

Jun

-14

Au

g-1

4

Oct-

14

Dec-1

4

Feb-1

5

Ap

r-15

Jun

-15

Au

g-1

5

Oct-

15

Dec-1

5

Feb-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

Dec-1

6

Feb-1

7

Ap

r-1

7

Jun

-17

Au

g-1

7

Oct-

17

Dec-1

7

Feb-1

8

£000

s

TAS Actual TAS Target

6,000

7,000

8,000

9,000

10,000

11,000

12,000

13,000

Ap

r-14

Jun

-14

Au

g-1

4

Oct-

14

Dec-1

4

Feb-1

5

Ap

r-15

Jun

-15

Au

g-1

5

Oct-

15

Dec-1

5

Feb-1

6

Ap

r-16

Jun

-16

Au

g-1

6

Oct-

16

Dec-1

6

Feb-1

7

Ap

r-17

Jun

-17

Au

g-1

7

Oct-

17

Dec-1

7

Feb-1

8

£000s

CMT Actual SCDT Actual CMT Budget SCDT Budget


35. Turnaround Time vs SLA (RCI) RCI # 5 36. Turnaround Time vs SLA (H&I) H&I # 7

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

95.0% 95.0% 98.6% G - 95.0% 95.0% 92.6% A -

37. Hospital Satisfaction - next survey results due in Jun 2017 H&I # 3 RCI # 3 38. Major QI's raised per month - DTS

Annual

Target

YTD

Target

YTD

ActualRAG

YTD RAG

Trend

60.0% 60.0% 53.0% R Worse

60.0% 60.0% 74.0% G -Percent of hospitals scoring =/> 9/10 for

satisfaction with H&I - RCI

Diagnostic and Therapeutic Services - Customer service and safety

Percentage of hospitals scoring =/> 9/10

for satisfaction with RCI - RCI

Turnaround Time vs SLA - H&I

YTD Performance

YTD Performance

Turnaround Time vs SLA - RCI

YTD Performance

60% 60% 60% 60%

68%

53%

75%

53%

60% 60% 60% 60%

73%

79%

86%

74%

40%

45%

50%

55%

60%

65%

70%

75%

80%

85%

90%

Jun

-16

Se

p-1

6

Dec-1

6

Mar-

17

RCI Target RCI survey H&I Target H&I survey

86.0%

88.0%

90.0%

92.0%

94.0%

96.0%

98.0%

100.0%

Ap

r-15

May-1

5

Jun

-15

Jul-1

5

Au

g-1

5

Se

p-1

5

Oct-

15

Nov-1

5

Dec-1

5

Jan

-16

Feb-1

6

Mar-

16

Ap

r-1

6

May-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

RCI Target RCI sample turnaround time vs SLA

84.0%

86.0%

88.0%

90.0%

92.0%

94.0%

96.0%

98.0%

100.0%

Ap

r-15

May-1

5

Jun

-15

Jul-1

5

Au

g-1

5

Se

p-1

5

Oct-

15

Nov-1

5

Dec-1

5

Jan

-16

Fe

b-1

6

Mar-

16

Ap

r-16

May-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Fe

b-1

7

Mar-

17

Ap

r-17

H&I target H&I sample turnaround time vs SLA

0

2

4

6

8

10

12

14

16

18

20

Ma

y-1

6

Jun

-16

Jul-

16

Aug

-16

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Fe

b-1

7

Ma

r-1

7

Apr-

17

BBMR H&INHS Cord Bank RCICMT Tissue ServicesTAS IBGRL - Molecular DiagnosticsCustomer Services


39. Adult donor provisions : UK and International - MATs SCDT # 8 40. Issue of cord blood units : UK and International - MATs SCDT # 7

SCDT # 8 SCDT # 8

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

216 16 15 R - 75 5 7 G -

41. Suitable Cornea Donations - MAT, and Cornea stocks 42. NHSBT CBB stock (active units - cell dose post process TNC) SCDT # 5

Annual

Target

YTD

Target

YTD

ActualRAG

YTD

RAG

Trend

2,300 191 171 R -

Adult donor provisions (total)

Stem Cell Donation and Transplantation, and Tissue and Eye Services : Corneas - Strategic Targets

YTD Performance

Banked Donations TNC > 140

YTD Performance

YTD Performance

Number of Cord Units Issued (total)

30

50

70

90

110

130

150

170

Ap

r-14

Ju

n-1

4

Au

g-1

4

Oct-

14

De

c-1

4

Fe

b-1

5

Ap

r-15

Ju

n-1

5

Au

g-1

5

Oct-

15

De

c-1

5

Fe

b-1

6

Ap

r-16

Ju

n-1

6

Au

g-1

6

Oct-

16

De

c-1

6

Fe

b-1

7

Ap

r-17

Ju

n-1

7

Au

g-1

7

Oct-

17

De

c-1

7

Fe

b-1

8

UK MAT International MAT UK Target International Target

200

220

240

260

280

300

320

340

360

3600

3700

3800

3900

4000

4100

4200

4300

4400

4500

Ma

y-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Fe

b-1

7

Ma

r-17

Ap

r-17

Co

rnea S

tock

Su

itab

le C

orn

ea D

on

ati

on

s M

AT

MAT Suitable Cornea Donations Cornea Stock

7,679

10,333

4,035

1,326

0

2,000

4,000

6,000

8,000

10,000

12,000

Less than 90 TNC(Research grade)

Between 90 to 139 TNC(Operational C Grade)

Between 139 to 190 TNC(Operational B Grade)

Greater than 190 TNC(Operational A Grade)

0

10

20

30

40

50

60

Apr-

14

Ju

n-1

4

Aug

-14

Oct-

14

Dec-1

4

Feb

-15

Apr-

15

Ju

n-1

5

Aug

-15

Oct-

15

Dec-1

5

Feb

-16

Apr-

16

Ju

n-1

6

Aug

-16

Oct-

16

Dec-1

6

Feb

-17

Apr-

17

Ju

n-1

7

Aug

-17

Oct-

17

Dec-1

7

Feb

-18

UK MAT International MAT UK Target International Target


of 32

Commentary - ODT • There were 113 deceased donors in April (versus target of 127). There were 62 DBD and 51 DCD donors in April and for DBD was the lowest monthly number of

donors since September 2016. The total of 113 deceased donors is lower than the monthly average achieved in 2016/17 (118) and also the monthly average achieved in Q4 2016/17 (121).

• April was a strong month for ODR overrides. Only 5 were recorded (versus a monthly average of 7.4 last year) and a SNOD was involved for each of them. • The overall consent rate in April has continued to report at Amber status for the sixth month in succession (65.5% vs 70%) but was better than the year end

position in 2016/17 of 62.7%. The SNOD involvement rates have continued to increase during April: DBD 94%, DCD 84% (compared with the average rates in


RAG CHANGE PERFORMANCE

Increase % Consent/Authorisation rate (Overall) A - April reporting at 65.5% (vs plan of 70%) - chart 55.

Increase % Consent/Authorisation rate (Overall) – DBD A Reporting at 68.5% in April (vs plan of 73%)

Increase % Consent/Authorisation rate (Overall) - DCD A Reporting at 63.7% for the full year (vs plan of 67%)

Deceased donors - 2017/18 target – 1,524 R - Deceased donors in April were 113 (vs 127) - chart 43.-

Deceased Organ Donors per million population - - Reported quarterly. March at 21.8m vs 22m planned.

Number of Living donors 2016/17 (1,260) – reported one month in arrears R - Year end at 1,039 (vs plan of 1,260) - chart 46.

Living Donors per million population – 19.0 per/m R Reported quarterly (one month in arrears). March 16.0m vs 19.5m planned.

Internal NHSBT target based on 1.1m new registrations in 2017/18. R - April at 72k registrations (vs 92k)

Organ Transplants – Deceased (4,116) R - 275 transplants in April (vs plan of 343) - chart 44.

Deceased Organ Transplants per million population. - - Reported quarterly. March at 57.3m vs 60.0m planned.

Proportion of population who have had a conversation about their donation decision - New measure, reported quarterly, next report: June 2017.

ODT

TOT 2020 Key Outcome Measures

NHSBT Cost per Transplant (chart 45). - £16.4k (2017/18 target) - - March at £18.1k. Next update June2017.

of 32

Q4 of DBD 92% / DCD 82%. April was a very strong month for the DCD consent rate (64%) and was the highest monthly DCD consent rate since February 2016 and also 5 percentage points higher than the average for Q4 2016/17 (59%). In contrast, the strong DBD consent rate of 72% achieved in Q4 2016/17, has slipped back to 68.5% in April.

• Although April was a strong month for referral rates there were 66 missed referral opportunities. In total 238 families were approached for an organ donation discussion during April, which was less than the monthly average of 262 for 2016/17. Therefore, although the overall consent rate from Q4 has been maintained (65%) and is higher than the overall consent rate for 2016/17 (63%), the number of consents (156) is lower than the 2016/17 monthly average of 164.

• The proportion of SNOD establishment who are competent on the rota is 75%; the highest it has been for a year. .

• There were 275 deceased transplants in April (versus target of 343). This was lower than the monthly average for 2016/17 (310) and also the monthly average for Q4 2016/17 (316). This was driven by both the lower number of deceased donors but also saw a low average number of transplantable organs per donor (3.17), he lowest it has been for four years

• In March 2017 there we 88 patients who received a transplant from a living donor. In the full year 2016/7 there were 1039 living donors, 17.5% (221) behind

target. • April was a better month for BAME consent with 15 out of 32 providing consent (46.9%). This is the highest return since October 2016, albeit it continues to be

lower than plan (55%). • There were 71k new registrations on the ODR in April (vs 92k target). The 2017/18 target is 1.1m new registrations.

• Absence has continued to remain low this month at 2.48%, lower than the previous year (2.9%).

. • Turnover overall in ODT saw a small decrease to 13.0% this month. There has been a number of retirements in Transplant Services and a more stable position

is expected over the next few months. ODT – Status of Strategic Projects per TPB reportin g:


Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)


Planned to complete

F/Cast to complete

Bristol Consolidation Initiation G G 0.9 1.3 0.5 Oct 17 May 18

ODT Hub Define A A 3.2 (i) (0.6) 4.1 N/A Dec 19 Dec 19

Note:

i) This is non recurring figure for 2017/18, recurring figure in brackets. .

43. MAT number of Deceased Organ Donors ODT # 4 44. MAT number of Deceased Donor Organ Transplants ODT # 9


TargetYTD Target YTD Actual YTD RAG

YTD RAG


Annual


YTD RAG

Trend

Number of Deceased Organ Donors 1524 127 113 R - Number of Deceased Donor Transplants 4116 343 275 R -

45. ODT Cost per Donor/Transplant ODT # 11 46. MAT number of Live Organ Donors (reported one month in arrears) ODT # 6

Annual

Target

Forecast

for the yearYTD RAG

YTD RAG


Annual


YTD RAG

Trend

16.4 16.2 G -Number of Living Organ Donors (reported one

month in arrears)1260 1260 1039 R -


Organ Donation and Transplant - Outcomes

YTD Performance

NHSBT Cost per Transplant (£k's)

0

500

1000

1500

2000

2500

3000

3500

4000

4500

0

10

20

30

40

50

60

70

80

10/11 11/12 12/13 13/14 14/15 15/16 16/17 Budget17/18

Forecast17/18

Do

no

rs/T

ran

sp

lan

ts (

No

.)

£

ODT Total Spend (£M) Cost per donor (£K) Cost per transplant (£K)

Transplants (No.) Donors (No.)

1418 1

524

17

64

1000

1100

1200

1300

1400

1500

1600

1700

1800

Apr-

17

May-1

7

Jun-1

7

Jul-

17

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

Jan-1

8

Feb-1

8

Ma

r-1

8

Ma

r-1

9

Ma

r-2

0

Mar-

21

Mar-

22

MAT Actual MAT Plan

3707

4116

5028

2800

3100

3400

3700

4000

4300

4600

4900

5200

Apr-

17

May-1

7

Jun-1

7

Ju

l-1

7

Au

g-1

7

Se

p-1

7

Oct-

17

Nov-1

7

Dec-1

7

Ja

n-1

8

Feb-1

8

Ma

r-1

8

Ma

r-1

9

Mar-

20

Ma

r-2

1

Mar-

22

MAT Actual MAT Plan

1089

1099

1078

10

70

1064

1056

1057

1060

1050

1042

1047

1039

1260

900

950

1000

1050

1100

1150

1200

1250

1300

1350

Ap

r-16

May-1

6

Ju

n-1

6

Ju

l-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Ja

n-1

7

Fe

b-1

7

Mar-

17

MAT Actual MAT Plan


47. MAT number of Deceased Organ Donors (DBD) 48. Deceased Organ Donors - Monthly (DBD)

49. Deceased Organ Donors - Weekly (DBD) 50. Deceased Organ Donors - Team (DBD)


Organ Donation and Transplant - DBD Activity

0

5

10

15

20

25

30

Ap

ril

May

Jun

e

July

Au

gust

Se

pte

mber

Octo

ber

Decem

ber

Ja

nu

ary

Febru

ary

Ma

rch

2017/18 Plan (DBD) 2017/18 Actual (DBD) 2016/17 Actual (DBD)

0

10

20

30

40

50

60

Engla

nd

Wale

s

Scotland

Nort

hern

Irela

nd

Organ donors YTD April 2016/17 (DBD) Organ donors YTD April 2017/18 (DBD)

834

834

888

500

550

600

650

700

750

800

850

900

950

Ap

r-1

6

Ma

y-1

6

Ju

n-1

6

Ju

l-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan

-17

Feb-1

7

Mar-

17

Apr-

17

May-1

7

Jun

-17

Jul-

17

Aug

-17

Sep

-17

Oct-

17

Nov-1

7

Dec-1

7

Jan

-18

Feb-1

8

Mar-

18

DBD MAT Actual DBD MAT Target

0

10

20

30

40

50

60

70

80

90

100


2016/17 DBD Actual 2017/18 DBD Actual 2017/18 DBD Target


51. MAT number of Deceased Organ Donors (DCD) 52. Deceased Organ Donors - Monthly (DCD)

53. Deceased Organ Donors - Weekly (DCD) 54. Deceased Organ Donors - Team (DCD)


Organ Donation and Transplant - DCD Activity

0

2

4

6

8

10

12

14

16

18

20

Ap

ril

May

Ju

ne

July

Au

gust

Se

pte

mber

Octo

ber

Decem

ber

Jan

uary

Fe

bru

ary

Marc

h

2017/18 Plan (DCD) 2017/18 Actual (DCD) 2016/17 Actual (DCD)

0

5

10

15

20

25

30

35

40

45

50

Engla

nd

Wale

s

Sco

tla

nd

No

rth

ern

Ire

land

Organ donors YTD April 2016/17 (DCD) Organ donors YTD April 2017/18 (DCD)

584

588

636

450

500

550

600

650

Ap

r-1

6

May-1

6

Jun

-16

Ju

l-1

6

Au

g-1

6

Sep

-16

Oct-

16

No

v-1

6

De

c-1

6

Ja

n-1

7

Feb-1

7

Mar-

17

Ap

r-1

7

Ma

y-1

7

Jun

-17

Jul-17

Au

g-1

7

Se

p-1

7

Oct-

17

No

v-1

7

De

c-1

7

Ja

n-1

8

Fe

b-1

8

Mar-

18

DCD MAT Actual DCD Target

0

10

20

30

40

50

60

70


2016/17 DCD Actual 2017/18 DCD Actual 2017/18 DCD Target


55. Consent / Authorisation rate (DBD & DCD) ODT # 1 56. Consent/Authorisation rate (DBD) per month ODT # 2



YTD RAG


Annual


YTD RAG

Trend

Consent/Authorisation rate (%) 70.0% 70.0% 65.5% A - DBD Consent/Authorisation rate (%) 73.0% 73.0% 68.5% A -

57. Consent/Authorisation rate (DCD) per month ODT # 3 58. Number of people registered on the ODR (opt-ins) ODT # 8



YTD RAG


Annual


YTD RAG

Trend

DCD Consent/Authorisation rate (%) 67.0% 67.0% 63.7% A - Opi-in registrants on the ODR (millions) 1.100 0.092 0.071 R -


Organ Donation and Transplant - Consent / ODR

000's

21.00

21.50

22.00

22.50

23.00

23.50

24.00

24.50

25.00

Apr-

16

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Ma

y-1

7

Jun-1

7

Jul-1

7

Aug-1

7

Sep-1

7

Oct-

17

No

v-1

7

De

c-1

7

Jan-1

8

Feb

-18

Ma

r-1

8

Registrants Target

50%

54%

58%

62%

66%

70%

74%

0

50

100

150

200

250

300

350

Ma

y-1

6

Jun-1

6

Ju

l-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Ap

r-1

7

Approach Consent Percent Target %

50%

54%

58%

62%

66%

70%

74%

78%

0

20

40

60

80

100

120

140

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Eligible DBD family approached DBD family consents Target Consent % Mthly %

50.0%

54.0%

58.0%

62.0%

66.0%

70.0%

74.0%

0

20

40

60

80

100

120

140

160

180

200

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Eligible DCD family approached DCD family consents Target Consent % Mthly %


59. Transplantable Organs per Donor 60. Duty Office - Incidents per Organ Offer

61. ODT Absence rate (%) 62. Annual Turnover rate (%)


Organ Donation and Transplant - Transplantable Organs / Incidents

Organ Donation and Transplant - Absence/Turnover

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug

-16

Sep

-16

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

DBD (Actual) DCD (Actual)

%

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

Ma

y-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Ja

n-1

7

Fe

b-1

7

Ma

r-17

Ap

r-17ODT Overall % absence Organ Donation % absence Transplant Support Services % absence

0

5

10

15

20

25

30

Ma

y-1

6

Ju

n-1

6

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan

-17

Fe

b-1

7

Ma

r-17

Ap

r-17

ODT % turnover ODT % turnover Transplant Support Services % turnover

0

500

1,000

1,500

2,000

2,500

3,000

3,500

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%

Ma

y-1

6

Jun-1

6

Jul-1

6

Aug-1

6

Sep-1

6

Oct-

16

No

v-1

6

De

c-1

6

Jan-1

7

Feb

-17

Ma

r-1

7

Apr-

17

Incid

en

t R

ate

Duty Office - Incidents per organ offer Organ Offers made


of 32

SECTOR NOTES/UPDATE REPORT

NHSBT Corporate

Sickness absence was lower in the month at 3.2%, lower than last year (3.6%) and also i2015/16 (3.92%). Actions are being taken to reduce long term sickness in blood donation in particular with a focus on improving the quality of the return to work interviews. Health and Safety – the Lost Time Incidence Rate (12 months to March 2017) for all work related lost time continues to be 1.9 – it will be reported on a monthly basis going forward. NHSBT introduced precautionary IT measures over the weekend of the 13/14th May (in response to worldwide cyber attack), including restrictions on remote access and opening attachments. These restrictions were removed on Monday, 15 May with staff being reminded of recent guidance, and to be especially vigilant when managing emails. As a result of the cyber attack, many hospitals could not use OBOS and needed to use alternative means of communicating with NHSBT, including faxes and telephones. The situation is improving with only one hospital continuing to see problems on May 15. Equality, diversity & human rights week 2017 runs from 15 to 19 May. As part of promoting awareness, teams are being asked to promote a related poster, with these being used as part of a photo gallery on Inside NHSBT.

Corporate - Status of Strategic Projects per TPB re porting – are reported on the following page:

of 32

TRANSFORMATION PROGARMME – GROUP LEVEL PROJECTS

Corporate - Status of Strategic Projects per TPB re porting


Last RAG

Approved Cost

(£m’s)

F/Cast Cost

(£m’s)


Planned to complete

F/Cast to complete

Brentwood Estates Optimisation Delivery R A 7.1 3.8 0.4 (i) May 17 Jul 17 Networks & Telephony Contract Delivery A A 1.0 1.0 N/A Apr 17 Oct 17 Oracle Database Upgrade Delivery G A 0.4 0.4 N/A Mar 17 Jun 17 Leeds Sheffield Initiation G G 16.4 16.4 N/A Jan 21 Jan 21 Next Generation Firewalls Managed Service Delivery A A 1.6 1.6 N/A Nov 16 Jun 17

Desktop Modernisation – Infrastructure Improvement Delivery R A 9.1 9.1 N/A Aug 17 Aug 17

Infrastructure Hosting Phase 2 Start-Up G G 0.1 N/A N/A TBC Mar 18 Pulse GUI/Middleware Server Upgrade Start-Up G G N/A N/A N/A TBC Apr 18

Note:

i) Benefits amended and approved to take account of cost and size of SHU and office properties.

63. IT system performance 64. Health and Safety - Accident Reporting

Period

Target

Period

Actual

Period

RAG

RAG

Trend

Level 1&2

MAT Target

Level 1&2 MAT

Total

Level 1-3

Mthly Target

Level 1-3

Period Actual

<24 17 =/<27 12

<9 5 =/<5 0

=/<1 1 =/<2 5

0 0 =/<1 0

0 0 =/<1 0

<34 23 =/<36 17

65. Headcount / WTE (as at payroll date) 66. Sickness Absence

Plan WTE

(Ave YTD)

YTD Ave

WTE (C)

Variance

WTE

Variance

%

775 804 -29 -3.8%

1,416 1,419 -4 -0.3%

849 793 55 6.5%

408 408 0 -0.1%

3,447 3,425 22 0.6%

3 4 -1 -20.3%

83 85 -3 -3.4%

73 67 6 8.4%

77 78 0 -0.6%

342 347 -5 -1.6%

96 93 3 3.6%

153 141 12 7.9%

169 156 13 7.9%

181 175 6 3.3%

33 37 -4 -13.4%

1 20 -18 -1355.9%

1,210 1,202 9 0.7%

4,657 4,627 31 0.7%

74% 74%

TMS

OBOS 99.95% 100.00%

Hematos

Blood Supply: Logistics

Finance

Better

Function

Blood Supply: Manufacturing, Testing & Issue

Diagnostic and Therapeutic Services

Blood Supply: Blood Donation

Organ Donation (including Group Services)

99.56% A

% Operational WTE to Total WTE

Sub-total Operational

Sub-total Group Service

Total

Quality

HR and BTS Project Management

Communications

Change Programme & Development

Research and Development

Clinical

CEO and Board

Estates & Facilities

BTS - Information Communication Technology

Pulse

R

Worse

G

99.95% 100.00% G Better

EOS 99.95% 100.00% G

NtXD 99.95%

H&S Incident Levels (x 1 mth

in arrears)

Blood Donation

DTS/SpS

NHSBT Corporate - ICT / Workforce

System availability

100.00% G BetterDonor Portal 99.95%

NHSBT

M&L

99.95% 100.00% G -

99.95% 98.83% Worse

Better

Organ Donation

Group Services

17

0

10

20

30

40

50

Ap

r-1

6

May-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

No

v-1

6

Dec-1

6

Jan

-17

Feb-1

7

Ma

r-1

7

Blood Supply - MTI / Donation DTS Organ Donation Group Services NHSBT Total

2016/17 Monthly Target (36)

2.50%

3.50%

4.50%

5.50%

6.50%

7.50%

8.50%

May-1

6

Jun

-16

Jul-1

6

Au

g-1

6

Se

p-1

6

Oct-

16

Nov-1

6

Dec-1

6

Jan

-17

Feb-1

7

Mar-

17

Ap

r-17

NHSBT Blood Donation Logistics


of 32

RISK MANAGEMENT Risk register summary ( net risk) and summary by themes

Corporate Risk Register Summary Red Amber Green

132 12 112 8

The dependency and reliance on the SME that currently provides support for our critical operational systems (PULSE/Hematos) and, in particular, their ability to retain the necessary capability and service levels as we transition away to new systems as part of the CSM project. The ability to supply in case of the loss of a key facility (e.g. Filton, Speke) or the loss of critical IT systems (Pulse, Hematos, networks etc). The risk of critical system loss is increasing on the back of the significant changes that are planned (e.g. new desktop, CSM etc.) and the significant complexity and inter-dependency between them. Inability to supply as a result of planning / supply challenges through: • (at the macro level) limited visibility with regard to longer term blood demand trends and especially when current demand decline

will be offset by the anticipated impact of demographic trends • significant differential short term demand trends at group / component level (eg O neg red cells, A neg platelets) The scale of the transformation programme across NHSBT will create a significant challenge on the capacity and capability of NHSBT to safely execute the change (both ICT and business resources) and a potential distraction to delivering business as usual. The ability to maintain blood prices remains highly dependant on our ability to manage the combined impact of : • the need to fund the significant investment in CSM (and uncertainty regarding the phasing of the spend and timescale) • the organisational focus required to safely implement CSM and a slow down in the delivery of underlying BAU efficiency

improvements • ongoing reduction in red cell (and now platelet) demand and the loss of related income and contribution • being able to generate significant productivity improvements in Blood Donation especially (given the inherent productivity gap

and high contribution to overall costs) and the significant impact on service configuration required. Ongoing reduction in demand will require significant changes to the configuration of blood collection services in order to not just maintain productivity but deliver the increased Blood 2020 targets. This would involve fewer / larger mobile sessions, greater use of fixed donor venues and much less collection activity in certain parts of the country. This may result in adverse donor reaction (and potentially attendance) if not managed and communicated well and an impact on supply if, for example, sufficient numbers of O neg donors cannot be retained. The high prevalence of manual, paper based and verbal processes throughout NHSBT’s operations, especially within reference testing and in the duty office within organ donation and transplant. Although these are mitigated by appropriate manual control checks, and new systems are removing transcription in some areas, there is a residual risk that these are ineffective and cause transcription errors that could lead to the death or harm of NHS patients.

of 32

RISK MANAGEMENT Risk register summary ( net risk) and summary by themes (cont.)

Risk to delivery of TOT 2020 strategic targets driven by : • adverse trends in the donor pool • inability to change consent levels • lack of funding required for supporting business cases in respect of consent strategy and new technologies • lack of transplant capacity. Changing clinical/commissioning intentions in Stem Cells - ie Cord Blood / BBMR, as a recommended treatment, impacting on the outcomes and therefore the future viability of these services.

There were no new high/extreme risks for review this month.

Income Budget Actual Variance2016-17 Actual

Budget Forecast

£k £k £k £k £k £kRevenue Cash Limit - Organ Donation & Transplantation 5,161 5,161 0 61,697 61,927 61,927Revenue Cash Limit - Diagnostic and Therapeutic Services 205 348 142 4,173 2,465 4,173Blood & Components Income 20,891 20,000 (891) 262,506 257,060 256,351Diagnostic and Therapeutic Services Income 5,030 5,407 377 65,377 70,216 68,508Research & Development 92 99 8 1,985 1,101 1,101Organ Donation & Transplantation Other Income 1,005 989 (16) 11,544 12,062 12,062All Other Income 528 431 (98) 7,266 7,001 7,061Total Income 32,912 32,434 (478) 414,548 411,830 411,183

ExpenditureCost of Sales - Blood Component Stock Movement (200) 990 1,190 (143) 0 (1,305)Cost of Sales - Tissues Stock Movement 0 14 14 42 0 0Organ Donation & Transplantation Operational Expenditure (5,198) (5,116) 82 (65,278) (66,710) (66,710)Blood Supply: Manufacturing, Testing & Issue (5,677) (5,587) 89 (70,607) (68,383) (68,033)Blood Supply: Blood Donation (6,206) (6,090) 117 (75,559) (71,344) (71,639)Blood Supply: Logistics (1,696) (1,701) (5) (21,175) (20,648) (20,648)Diagnostic and Therapeutic Services (5,104) (4,896) 208 (60,293) (61,003) (61,407)Quality (419) (400) 18 (4,783) (5,023) (5,023)Chief Executive and Board (52) (47) 4 (623) (621) (621)Communications (367) (338) 28 (7,397) (7,348) (7,348)Estates & Facilities (3,053) (3,012) 41 (40,182) (39,288) (39,288)Finance (469) (462) 8 (5,760) (5,635) (5,635)HR and BTS Project Management (781) (753) 28 (9,117) (9,372) (9,372)BTS - Information Communication Technology (1,855) (1,831) 24 (20,661) (22,261) (22,761)Clinical Directorate (1,181) (1,155) 26 (14,014) (14,153) (14,153)Research & Development (373) (378) (5) (5,627) (4,486) (4,486)Change Programme & Development (1,999) (2,167) (168) (17,850) (27,409) (27,270)Miscellaneous and Capital Charges (159) (150) 9 (439) (1,910) (1,910)Total Expenditure (34,789) (33,080) 1,710 (419,467) (425,592) (427,609)

Surplus/(Deficit) (1,877) (646) 1,232 (4,919) (13,762) (16,426)

Statutory Accounts PresentationNHSBT Surplus/(Deficit) as above (1,877) (646) 1,232 15,658 (13,762) (16,426)Add back Notional Cost of Capital 593 593 0 7,176 7,121 7,121

Remove Revenue Cash Limit (5,366) (5,508) (142) (65,870) (64,391) (66,100)Deduct Capital Charges Cash Payment (1,462) (1,462) 0 (16,267) (17,544) (17,544)

Net Expenditure (8,112) (7,023) 1,089 (59,303) (88,577) (92,949)

A deficit of £0.6m was reported in April, £1.2m better than plan.

This reflects a favourable movement in Cost of Sales / higher RC stocks (£1.2m), a DTS I&E surplus of £0.7m and positive variances in group services costs (£0.2m), partially offset by lower sales within Blood Components (£0.9m).

Subject to the formal Q1 process, an initial forecast outturn for the year is suggesting a £16.4m deficit (vs £13.8m budgeted). This takes into account lower income in blood components (£0.7m), an adverse cost of sales movement (£1.3m) and additional funding allocated within transformation funds to recruit black donors (£1.0m).

Balance sheet - current assets were £57.9m at the end of April 2017, including a cash balance of £30.4m.

Debtor days - were 28 in April vs target 22 days.

NHSBT REVENUE STATEMENT - FOR THE PERIOD ENDED 30 APRIL 2017

Year to date Full year

of 32

board performance report performance report · page 1 of 32 board performance report performance...

Documents